Weight loss is similar between drug classes-nearly 2 kg (4 lb, 6 oz) with SGLT-2 inhibitors and 1.5 kg (3 lb, 5 oz) with GLP-1 receptor agonists. GLP-1 receptor agonists are less beneficial and have common gastrointestinal effects, leading to a recommendation for slow dose tapering. And, like any medication, there is a risk of side effects, some serious. Prescribing choices should be based on patient preferences, medication adverse effects, and cost. _ To reduce overall mortality in patients with type 2 diabetes mellitus, the BMJ/MAGIC Group recommends prescribing SGLT-2 inhibitors in those with cardiovascular disease and/or chronic kidney disease or three or more risk factors for cardiovascular disease. While several participants had complicated thoughts about the medications - some were frustrated with the cost, side effects or reaching a plateau - many described immensely positive effects on their overall health. In these very high-risk patients, GLP-1 receptor agonists reduce overall mortality, with an NNT of 42 (95% CI, 29 to 84) over five years. 860; 95% CI, 489 to 3,584) compared with placebo. 268; 95% CI, 147 to 1,565), but they did not reduce myocardial infarctions or hospitalizations from heart failure, compared with placebo. 109; 95% CI, 67 to 286) provided renal protection vs.

Look at my web-site; ColonBroom supplement